Specify a stock or a cryptocurrency in the search bar to get a summary
Annovis Bio Inc
ANVSAnnovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania. Address: 101 Lindenwood Drive, Malvern, PA, United States, 19355
Analytics
WallStreet Target Price
34.8 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ANVS
Dividend Analytics ANVS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ANVS
Stock Valuation ANVS
Financials ANVS
Results | 2019 | Dynamics |